Connecticut saw a drop in Respiratory Syncytial Virus, or RSV, cases during the 2025 season, according to statistics by the ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...